- CEO
- Jong-Ho Hong
- Full Time Employees
- 172
- Sector
- Process industries
- Industry
- Chemicals: specialty
- Address
- Anyang-si South Korea
- IPO Date
- Dec 19, 2018
- Business
- KUKJEON Co.,Ltd. is a South Korea-based fine chemical and pharmaceutical manufacturing company specializing in the research, development, synthesis, and commercial supply of active pharmaceutical ingredients, finished drug formulations, and high-purity advanced electronic materials. Founded in 1972 and headquartered in Anyang-si, Gyeonggi-do, South Korea, the company is publicly traded on the KOSDAQ market of the Korea Exchange under ticker 307750. Operating primarily through its Pharmaceutical and Advanced Electronic Materials divisions, the company delivers precision chemical solutions to healthcare providers, pharmaceutical manufacturers, semiconductor fabricators, display panel producers, and energy storage manufacturers across domestic and international markets, including Japan and Europe.
The company's primary product and service portfolio encompasses: active pharmaceutical ingredients (APIs), including itopride hydrochloride for functional gastrointestinal disorders, nafamostat mesylate for anticoagulation and acute pancreatitis, as well as synthetic ingredients for cardiovascular, respiratory, antimicrobial, and central nervous system therapeutics; finished dosage pharmaceutical products, comprising ethical prescription pharmaceuticals, incrementally modified drugs, and oral solid-dosage generic medications supplied to hospital and clinic networks; advanced semiconductor materials, notably high-purity precision cleaning agents and chemical precursors engineered for artificial intelligence (AI) semiconductor packaging processes; display and optoelectronic chemicals, consisting of organic light-emitting diode (OLED) intermediate compounds, quantum-dot (QD) OLED anti-reflective film materials, and optical polymers for foldable display applications; and secondary battery materials, including specialized functional electrolyte additives designed to enhance the stability, cycle life, and thermal resistance of electric vehicle batteries.
In recent strategic and corporate developments, the company officially changed its corporate name from Kukjeon Pharmaceutical Co., Ltd. to KUKJEON Co.,Ltd. in 2026, broadening its registered corporate objectives to cover precision chemical manufacturing and signaling its structural transformation into an integrated total chemical solution provider. To support its materials portfolio, the company completed and commissioned a KRW 50 billion advanced electronic materials production facility in Eumseong, Chungcheongbuk-do, securing domestic mass-production capabilities for AI semiconductor packaging chemicals and next-generation display components. Within its pharmaceutical operations, KUKJEON secured a commercial API supply agreement with Dongsung Pharmaceutical for the photosensitizer Phonogen and established research and development partnerships with Hanlim Pharm and Dr. InB for photoreactive oncology therapeutics. Additionally, the company expanded its global footprint through KS Biologics, a joint venture established with SN BioScience, by partnering with Germany-based oncology firm Akvida for the European commercialization and distribution of specialized anticancer therapies, alongside collaborating with EniSolution to implement advanced osmotic-release oral system (OROS) drug delivery technologies.